ClinicalTrials.gg
CompletedNCT01941836Updated Mar 29, 2019

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

A Phase 2 interventional study of ETC-1002 and Ezetimibe in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 68 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
5th of 21
349 · median 126
Started
2013
the only one that year
Phase 2
10 of 21
none open now
Registered
3rd of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 10 in phase 2, and was the 3rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this research study is to see how ETC-1002 is tolerated in the body, to measure the amount of ETC-1002 in the blood, and to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine in patients with elevated LDL-cholesterol with or without statin intolerance.

Read the detailed description

Hypercholesterolemic patients either with or without a history of statin intolerance (1:1 ratio) will be randomized to receive once daily by mouth capsules containing either ETC-1002, ezetimibe, or ETC-1002 + ezetimibe. This study will explore the safety and efficacy of concomitant administration of ETC-1002 and ezetimibe, while also exploring the effect of ezetimibe on ETC-1002 systemic exposure.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Statin intolerant
  • Statin tolerant
  • LDL
  • Cholesterol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Statin intolerant and statin tolerant
  • Fasting LDL-C between 130 mg/dL and 220 mg/dL
  • Fasting triglyceride less than or equal to 400 mg/dL
  • (BMI) between 18 and 45 kg/m2

Key Exclusion Criteria:

  • History or current cardiovascular disease
  • History or current type 1 diabetes or uncontrolled type 2 diabetes
  • Use of metformin or thiazolidinediones (TZD) within 3 months of screening
  • History of joint symptoms difficult to differentiate from myalgia
  • Uncontrolled hypothyroidism
  • Liver disease or dysfunction
  • Renal dysfunction or nephritic syndrome
  • Gastrointestinal (GI) conditions or prior GI procedures
  • or AIDS
  • History or
  • History or drug or alcohol abuse within last 2 years
  • Use of experimental or drugs within 30 days of screening
  • Use of ETC-1002 in a previous clinical study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
349 participants (actual)

Study arms

  • Experimental
    ETC-1002 120 mg/day

    Orally, once daily in morning as capsules

    Drug: ETC-1002

  • Experimental
    ETC-1002 180 mg/day

    Orally, once daily in morning as capsules

    Drug: ETC-1002

  • Active comparator
    ezetimibe 10mg/day

    Orally, once daily in morning as capsules

    Drug: Ezetimibe

  • Experimental
    ETC-1002 120 mg/day + ezetimibe 10mg/day

    Orally, once daily in morning

    Drug: ETC-1002 · Drug: Ezetimibe

  • Experimental
    ETC-1002 180 mg/day + ezetimibe 10mg/day

    Orally, once daily in morning

    Drug: ETC-1002 · Drug: Ezetimibe

Interventions

  • Patients receive ETC-1002

  • Patients receive ezetimibe

    Also known as: Zetia

06

What researchers measure

Primary outcomes

  1. Percent change in calculated low density lipoprotein-cholesterol (LDL-C)

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Percent change in other lipid measures non high density lipoprotein cholesterol (nonHDL-C)

    Time frame: Baseline and 12 weeks

  2. Safety using adverse event reports; vital signs

    Time frame: up to 21 weeks including screening

  3. Percent change in Apolipoprotein B (ApoB)

    Time frame: Baseline and 12 weeks

  4. Percent change in high sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline and 12 weeks

  5. Safety using adverse event reports; clinical laboratory results

    Time frame: up to 21 weeks including screening

  6. Safety using adverse event reports; rates of muscle-related adverse

    Time frame: up to 21 weeks including screening

Other outcomes

  1. Pharmacokinetic plasma trough concentrations of ETC-1002 and its metabolite ESP15228

    Time frame: Week 2, Week 4, Week 8 and Week 12

07

Study locations

68 sites
  • Birmingham, Alabama 35209, United States
  • Muscle Shoals, Alabama 35662, United States
  • Chandler, Arizona 85224, United States
  • Beverly Hills, California 90211, United States
  • Chino, California 91710, United States
  • Lincoln, California 95821, United States
  • Long Beach, California 90806, United States
  • Los Angeles, California 90059, United States
  • Newport Beach, California 92663, United States
  • Thousand Oaks, California 91360, United States
  • Vista, California 92083, United States
  • Denver, Colorado 80220, United States
  • Hartford, Connecticut 06102, United States
  • Atlantis, Florida 33462, United States
  • Brandon, Florida 33511, United States
  • Hialeah, Florida 33012, United States
  • Jacksonville, Florida 32223, United States
  • Oviedo, Florida 32765, United States
  • Ponte Vedra, Florida 32081, United States
  • Port Orange, Florida 32127, United States
  • Saint Petersburg, Florida 33756, United States
  • West Palm Beach, Florida 33409, United States
  • Decatur, Georgia 30033, United States
  • Marietta, Georgia 30066, United States
  • Meridian, Idaho 83646, United States
  • Evansville, Indiana 47714, United States
  • Kansas City, Kansas 66214, United States
  • Auburn, Maine 04210, United States
  • Lincoln, Nebraska 68510, United States
  • Clifton, New Jersey 07012, United States
  • Albuquerque, New Mexico 87106, United States
  • New Windsor, New York 12553, United States
  • Rochester, New York 14609, United States
  • Williamsville, New York 14221, United States
  • Greensboro, North Carolina 27408, United States
  • Raleigh, North Carolina 27609, United States
  • Salisbury, North Carolina 28144, United States
  • Wilmington, North Carolina 28401, United States
  • Beachwood, Ohio 26900, United States
  • Cincinnati, Ohio 45219, United States
  • Cincinnati, Ohio 45227, United States
  • Cleveland, Ohio 44195, United States
  • Columbus, Ohio 43213, United States
  • Franklin, Ohio 45005, United States
  • Lyndhurst, Ohio 44124, United States
  • Marion, Ohio 43302, United States
  • Willoughby Hills, Ohio 44094, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Tulsa, Oklahoma 74136, United States
  • Eugene, Oregon 97404, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Kingsport, Tennessee 37660, United States
  • Austin, Texas 78731, United States
  • Dallas, Texas 75216, United States
  • Dallas, Texas 75230, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77030, United States
  • Houston, Texas 77072, United States
  • Houston, Texas 77074, United States
  • Round Rock, Texas 78681, United States
  • Orem, Utah 84058, United States
  • Salt Lake City, Utah 84124, United States
  • Norfolk, Virginia 23502, United States
  • Richmond, Virginia 23294, United States
  • Olympia, Washington 98502, United States
  • Renton, Washington 98057, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99204, United States
08

References and documents

Publications

  • Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13. PubMed 23770179 ↗
  • Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, Srivastava RAK, Hurley TR, Bradshaw CD, Spahr MA, Newton RS. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-2108. doi: 10.1194/jlr.M035212. Epub 2013 May 24. PubMed 23709692 ↗
  • Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51. doi: 10.1194/jlr.M030528. Epub 2012 Nov 1. PubMed 23118444 ↗
  • Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2. PubMed 24385236 ↗
  • Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun;10(3):556-67. doi: 10.1016/j.jacl.2015.12.025. Epub 2016 Jan 6. PubMed 27206943 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Oct 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2013
First posted
Sep 13, 2013
Start
Sep 2013
Primary completionActual
Oct 2014
CompletionActual
Nov 2014
Results delay requested
Aug 13, 2015
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01941836
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Sep 13, 2013
Start date
Sep 2013
Primary completion
Oct 2014
Completion
Nov 2014
Last update
Mar 29, 2019

Study contacts

Diane E MacDougall, MS
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bempedoic acid · Ezetimibe

Start the discussion